Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 52-Week Low – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $29.00 and last traded at $29.00, with a volume of 24,865 shares changing hands. The stock had previously closed at $41.92.

Analyst Ratings Changes

A number of equities analysts have weighed in on SUPN shares. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings cut Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $62.33.

Supernus Pharmaceuticals Stock Down 28.3%

The firm’s fifty day moving average price is $42.42 and its 200 day moving average price is $47.27. The stock has a market cap of $1.75 billion, a PE ratio of -39.01, a P/E/G ratio of 1.21 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million for the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.80) earnings per share. As a group, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The company also recently disclosed a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be given a dividend of $8.13 per share.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Summit Global Investments raised its holdings in shares of Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after acquiring an additional 256 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Supernus Pharmaceuticals by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after buying an additional 321 shares during the period. Corient Private Wealth LP lifted its position in Supernus Pharmaceuticals by 6.6% in the second quarter. Corient Private Wealth LP now owns 5,163 shares of the specialty pharmaceutical company’s stock worth $240,000 after buying an additional 321 shares during the last quarter. Juncture Wealth Strategies LLC boosted its stake in Supernus Pharmaceuticals by 5.8% during the third quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company’s stock worth $292,000 after buying an additional 374 shares during the period. Finally, Versant Capital Management Inc increased its position in Supernus Pharmaceuticals by 47.2% during the third quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.